BURLINGTON, Mass., Aug. 12, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences will be hosting its 25th anniversary and the launch of its annual GENEWIZ Week event on September 16 - 20. GENEWIZ Week will showcase our commitment to providing cutting-edge solutions to researchers worldwide through a series of workshops, an awards program, and engaging prizes and promotions.
Registration for GENEWIZ Week 2024 is now open.
"We are thrilled to celebrate our 25th anniversary during our annual GENEWIZ Week event," said Ginger Zhou, Senior Vice President & General Manager – GENEWIZ Multiomics and Synthesis Solutions. "Our team is committed to providing researchers with the tools and support they need to make significant scientific discoveries, and we are excited to help the research community create a healthier world."
GENEWIZ Week is a must-attend event for researchers looking to stay at the forefront of genomics research. For more information and to participate in the weeklong event full of learning, networking, and celebration, please visit the GENEWIZ Week event page.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey and B Medical Systems.
Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.
INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial, Planning & Analysis and Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Sherry Dinsmore
This email address is being protected from spambots. You need JavaScript enabled to view it.
Azenta's use of third-party trademarks and brands are for identification only and does not imply affiliation or endorsement. All trademarks used herein are the property of their respective owners.
Last Trade: | US$33.51 |
Daily Change: | 2.08 6.62 |
Daily Volume: | 1,115,068 |
Market Cap: | US$1.530B |
May 13, 2025 November 12, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load